Head and Neck Cancer Research and Clinical Trials

Kirin Tissue Registry

Assessment of efficacy of drug candidates which induce tumor immunity in melanoma or squamous cell carcinoma (SCC) of the head and neck

  • Primary or metastatic SCC of the head and neck or melanoma
  • Planned surgical resection of SCC head and neck tumors
  • Need three 5-mm cubes (~2 mm3 total)

Coordinator: Suzanna Lee, sml012@ucsd.edu

GeneLux GLONC-1 005

Phase 1 trial of IV genetically modified Vaccinia virus (GL-ONC1) with concurrent Cisplatin and radiotherapy for locoregionally advanced head and neck carcinoma

  • Stage III to IVb primary, non-metastatic head and neck cancer for newly diagnosed patients with no prior disease-related treatments
  • Must be HIV and P16 negative

Coordinator: Sara-Jane Onyeama, sonyeama@ucsd.edu

RTOG 1008: Randomized Phase II study of adjuvant concurrent radiation and chemotherapy versus radiation alone in resected high-risk malignant salivary gland tumors.

  • Malignant major salivary glands, subtypes: high grade mucoepidermoid carcinoma, salivary duct carcinoma or high grade adenocarcinoma; minor salivary glands excluded
  • Surgical resection with curative intent within 8 weeks prior to registration
  • T3-T4 or N1-3 or T1-2 N0 with a close (1 mm) or microscopically positive surgical margin; M0

Coordinator: Sara-Jane Onyeama, sonyeama@ucsd.edu

RTOG 1016: Phase III trial of radiotherapy plus Cetuximab versus chemotherapy in HPV-associated oropharynx cancer

  • SCC of the oropharynx (tonsil, base of tongue, soft palate, oropharyngeal walls)
  • Measurable disease at the primary site of nodal stations
  • T1-2, N2a-N3 or T3-4, and N, M0

Coordinator: Sara-Jane Onyeama, sonyeama@ucsd.edu

RTOG 0920: Phase III study of post-operative radiation therapy (IMRT) +/- Cetuximab for locally-advanced head and neck cancer

  • SCC of the head and neck
  • Clinical stage T1, N1-2 or T2-3, N0-2, M0
  • GTR within 7 weeks of registration
  • At least one "intermediate" risk factor: Perineural invasion; LVI, Single lymph node > 3 cm or = 2 lymph nodes (all < 6 cm) [no extracapsular extension]; close margin(s) or resection (within 5 mm of surgical margin); T3 or microscopic T4a primary tumor, T2 oral cavity cancer with > 5 mm depth of invasion

Coordinator Sara-Jane Onyeama, sonyeama@ucsd.edu

More Head and Neck Cancer Clinical Trials